Risks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial...

Area of Science:

• Cardiology
• Clinical Medicine
• Pharmacology

Background:

• ST-elevation myocardial infarction (STEMI) treatment involves multiple drug classes and procedures.
• The optimal combination of thrombolytics, anticoagulants, antiplatelets, and primary angioplasty (PA) requires ongoing evaluation.
• Assessing the balance between therapeutic benefits and bleeding risks is crucial.

Purpose of the Study:

• To evaluate the impact of combining thrombolytics, anticoagulants, antiplatelets, and PA on mortality, reinfarction (AMI), and major bleeding (MB) in STEMI.
• To analyze the correlation between the number of drugs used, PA, and study publication year with patient outcomes.

Main Methods:

• A systematic literature search of randomized trials in Medline was conducted.
• Studies included at least 500 patients and reported rates of death, AMI, and MB.
• Data from 59 eligible papers involving 404,556 patients were analyzed for correlations.

Main Results:

• A higher number of drugs correlated with increased rates of death and major bleeding (MB).
• Primary angioplasty (PA) was associated with lower mortality but increased MB.
• Publication year showed correlations with reduced death and AMI, and increased MB, indicating evolving treatment effectiveness.

Conclusions:

• Increasingly complex STEMI treatment regimens have led to significant reductions in mortality.
• Concurrent increases in major bleeding (MB) rates are observed with more complex treatments.
• Despite increased bleeding risks, the overall benefits of modern STEMI therapies outweigh the associated risks.